Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis.
Victoria G HallC LimN R SaundersE KlimevskiT H O NguyenL KedzierskiJohn Francis SeymourV WadhwaK A ThurskyM K YongK KedzierskaM A SlavinBenjamin W TehPublished in: Leukemia & lymphoma (2023)